Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uliledlimab + Toripalimab vs Pembrolizumab in PD-L1+ CD73+ NSCLC
NCT06984588Phase 3Active, not recruiting
- Sponsor
- TJ Biopharma
- Start
- Mar 2024
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of uliledlimab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by TJ Biopharma. Primary endpoint: Progression-Free Survival at 6 months. Started Mar 2024; status: active, not recruiting.
02
Drugs
uliledlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06984588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06984588.